Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.5.1.3: dihydrofolate reductase

This is an abbreviated version!
For detailed information about dihydrofolate reductase, go to the full flat file.

Word Map on EC 1.5.1.3

Reaction

5,6,7,8-tetrahydrofolate
+
NADP+
=
7,8-dihydrofolate
 +
NADPH
 +
H+

Synonyms

5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, 7,8-dihydrofolate reductase, At2g16370, At4g34570, bifunctional dihydrofolate reductase-thymidylate synthase, bifunctional TS-DHFR, BmDHFR, dehydrogenase, tetrahydrofolate, DFR-TS, DFR1, DfrA, DfrB, DHFR, DHFR type IIIC, DHFR-TS, DHFR-TS1, DHFR-TS2, DHFR2, DHFRL1, DHFRLS, dihydrofolate reductase, dihydrofolate reductase-like, dihydrofolate reductase-thymidylate synthase, dihydrofolate reductase:thymidylate synthase, dihydrofolic acid reductase, dihydrofolic reductase, EC 1.5.1.4, ecDHFR, folA, folA3, folic acid reductase, folic reductase, FolM, hDHFR, hDHFR-1, hDHFR-2, HjDHFR, hvDHFR1, hvDHFR2, LAU_0427, LBRM_06_0830, mDHFR, mjDHFR, More, myDHFR, NADPH-dihydrofolate reductase, pcDHFR, PKNH_0509600, ppDHFR, pteridine reductase, pteridine reductase:dihydrofolate reductase, PTR2, R-plasmid-encoded dihydrofolate reductase, R67 DHFR, R67 dihydrofolate reductase, reductase, dihydrofolate, S3DHFR, Smdhfr, Smp 175230, spDHFR, svDHFR, tcptr1, tetrahydrofolate dehydrogenase, THY-1, THY-2, thymidylate synthase-dihydrofolate reductase, thymidylate synthetase-dihydrofolate reductase, Trimethoprim resistance protein, TS-DHFR, WUBG_00817

ECTree

     1 Oxidoreductases
         1.5 Acting on the CH-NH group of donors
             1.5.1 With NAD+ or NADP+ as acceptor
                1.5.1.3 dihydrofolate reductase

Inhibitors

Inhibitors on EC 1.5.1.3 - dihydrofolate reductase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-epicatechin
(-)-epicatechin gallate
(-)-epigallocatechin gallate
-
competitive to 7,8-dihydrofolate, formation of a slow dissociation ternary complex by the reaction of NADPH with the enzyme-inhibitor complex. Ionization state of E30 is critical for inhibitory activity
(1E)-1-[4-[(3,5-dichloropyridin-4-yl)oxy]phenyl]ethanone thiosemicarbazone
-
-
(2,4-diaminopyrimidin-5-yl)methyl naphthalene-2-sulfonate
(2,5-dimethyl-1,4-phenylene)bis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
50% inhibition at 0.000075 mM
(2-(4-((2,4-diaminopyrimidine-5-yl)methyl)-2,6-dimethoxyphenoxy)-2-oxoethyl)glutamic acid
16fold selectivity for Leishmania major enzyme over human enzyme
-
(2-(4-((2,4-diaminopyrimidine-5-yl)methyl)-2,6-dimethoxyphenoxy)-2-oxoethyl)leucine
84fold selectivity for Leishmania major enzyme over human enzyme
-
(2-(4-((2,4-diaminopyrimidine-5-yl)methyl)-2,6-dimethoxyphenoxy)-2-oxoethyl)phenylalanine
87fold selectivity for Leishmania major enzyme over human enzyme
-
(2-(4-((2,4-diaminopyrimidine-5-yl)methyl)-2,6-dimethoxyphenoxy)-2-oxoethyl)tryptophan
10fold selectivity for Leishmania major enzyme over human enzyme
-
(2E)-1-(1-cyclohexylphthalazin-2(1H)-yl)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-(1-phenoxyphthalazin-2(1H)-yl)prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-(1-phenylphthalazin-2(1H)-yl)prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-(1-propylphthalazin-2(1H)-yl)prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(2-methylphenyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(3,3,3-trifluoropropyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(3,5-dimethylphenyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(3-fluorophenyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(3-methylbut-2-en-1-yl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(3-methylbutyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(4-fluorophenyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(4-methoxyphenoxy)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(4-methylphenoxy)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(4-methylphenyl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(hexan-3-yl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-(propan-2-yl)phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2E)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]-1-[1-[4-(trifluoromethoxy)phenoxy]phthalazin-2(1H)-yl]prop-2-en-1-one
-
(2S)-2-((4-[(2-amino-6-ethyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
50% inhibition at 0.00042 mM, additionally inhibitory on thymidylate synthase
(2S)-2-((4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl)amino)pentanedioic acid
50% inhibition at 0.0021 mM, additionally inhibitory on thymidylate synthase
(2S)-2-[(4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)phenyl)formamido]pentanedioic acid
i.e, methotrexate, A DHFR inhibitor, binds at the DHFR active site
(2S)-2-[(5-{methyl[(2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid
-
in low-folate medium, up to 300-fold increase of inhibitory activity
(4-(1-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]ethyl)phenyl)methanol
(E)-1-(1-cyclopropyl-6,7-dimethoxyphthalazin-2(1H)-yl)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)prop-2-en-1-one
-
-
(E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-(4-methoxyphenyl)phthalazin-2(1H)-yl)prop-2-en-1-one
-
-
(E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-phenylphthalazin-2(1H)-yl)prop-2-en-1-one
-
-
(E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-propylphthalazin-2(1H)-yl)prop-2-en-1-one
-
-
(E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(6,7-dimethoxy-1-propylphthalazin-2(1H)-yl)prop-2-en-1-one
-
-
(E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(6,7-dimethyl-1-propylphthalazin-2(1H)-yl)prop-2-en-1-one
-
-
(E)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
(Z)-5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamine
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-benzylpyrazinediium)
-
minimal inhibitory concentration: 0.003536 mM
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-methylpyrazinediium)
-
minimal inhibitory concentration: 0.002418 mM
1,1'-{6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}bis(4-phenylpyrazinediium)
-
minimal inhibitory concentration: 0.018 mM
1,3-phenylenebis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
50% inhibition at 0.000075 mM
1,4-bis-([N-(1-imino-1-guanidino-methyl)]sulfanylmethyl)-3,6-dimethyl-benzene
binding of the inhibitor has both a favorable entropy and enthalpy of binding. Positive binding cooperativity between inhibitor and the cofactor NADPH. Binding of inhibitor to DHFR is 285fold tighter in the presence of the NADPH cofactor than in its absence
1,4-phenylenebis(methylene) bis(N-[amino(imino)methyl](imidothiocarbamate))
-
1,6-bis-(4-fluoro-phenyl)-[1,3,5]triazine-2,4-diamine
-
IC50: 0.011 nM, 0.03 mM 7,8-dihydrofolate
1-(3,4-dichlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
competitive inhibition
1-(3,4-dichlorophenyl)-6-(4-nitrophenyl)-1,6-dihydro-1,3,5-triazine-2,4-diamine
competitive inhibition
-
1-(3-([(2,4-diaminopteridin-6-yl)methyl]amino)phenyl)ethanol
1-(3-ethoxyphenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
1-(4-chlorophenyl)-6-methyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
competitive inhibition
-
1-(4-chlorophenyl)-6-propyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
competitive inhibition
-
1-(4-ethoxyphenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
1-(4-methoxyphenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
competitive inhibition
-
1-(4-nitrophenyl)-3-[4-[4-[(4-nitrophenyl)carbamoylamino]phenoxy]phenyl]urea
NSC80735, complete inhibition at 1 mM
1-([N-(1-imino-guanidino-methyl)]sulfanylmethyl)-3-trifluoromethyl-benzene
binding of the inhibitor has both a favorable entropy and enthalpy of binding. Positive binding cooperativity between inhibitor and the cofactor NADPH. Binding of inhibitor to DHFR in the absence of NADPH is not observed
1-N,4-N-bis(4-aminophenyl)benzene-1,4-dicarboxamide
NSC55152, complete inhibition at 1 mM
1-[3-(3,4-dichlorophenoxy)propyloxy]-5-isopropylbiguanide
-
i.e. PS-16
1-[3-(4-chlorophenoxy)propyloxy]-5-isopropylbiguanide
-
i.e. PS-33
1-[3-(aminomethyl)phenyl]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
1-[3-chloro-4-(5-phenylpentyl)phenyl]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
uncompetitive versus NADPH, competitive versus 7,8-dihydrofolate
1-[4-(aminomethyl)phenyl]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
1-[4-(dimethylamino)phenyl]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
1-[4-[4-(2,4-dichlorophenyl)butyl]phenyl]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
11H-benzo[b][1]benzazepine
NSC123458, 87% inhibition at 1 mM
2,2'-({6-[(4-nitrophenyl)amino]-1,3,5-triazine-2,4-diyl}diimino)diethanol
-
minimal inhibitory concentration: 0.149 mM
2,3-bis(hydrazino)quinoxaline
-
-
2,4,6-Trinitrobenzenesulfonic acid
-
-
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine
-
-
2,4-diamino-5-((R)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
2,4-diamino-5-((S)-3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine
i.e. UCP120B, potent enzyme inhibitor of DHFR and bacterial growth, three-dimensional solution structure of the ternary complex with enzyme and NADPH cofactor determined by NMR from 20 mM TES, 50 mM KCl, 10 mM DTT, and 0.5 mM EDTA solution containing 2 mM of each ligand, comparison to the crystal structure of the ternary complex, overview. Analysis of structure and dynamics of the binary inhibitor-enzyme complex
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)-6-methylpyrimidine
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)but-1-ynyl)pyrimidine
2,4-diamino-5-(3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
2,4-diamino-5-(3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-ynyl)-6-methylpyrimidine
2,4-diamino-5-(3-phenylprop-1-ynyl)-6-ethylpyrimidine
2,4-Diamino-5-adamantylpyrimidine
2,4-Diamino-5-benzylpyrimidines
-
-
2,4-diamino-5-isopropyl-6-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-isopropyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(1-naphthylthio)furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2',3',5',6'-tetrafluoro-4'-trifluoromethylphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2',5'-dimethoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2',6'-dichlorophenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2',6'-dimethylphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2'-isopropyl-6'-methylphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(2-naphthylthio)furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(3',4'-dimethoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(3'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-6-(4'-methoxyphenylsulfanyl)-furo[2,3-d]pyrimidine
2,4-diamino-5-methyl-butylpyrido[2,3-d]pyrimidine
-
-
2,4-Diamino-5-phenyl-s-triazines
-
-
2,4-diamino-5-propyl-6-(1'-naphthylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine
-
-
2,4-diamino-5-propyl-6-arylthio-7H-pyrrolo[2,3-d]pyrimidine
2,4-diamino-5-[(R)-3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[(S)-3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(2,3-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]-6-npropylpyrimidine
2,4-diamino-5-[3-(2,5-dimethoxyphenyl)prop-1-ynyl]pyrimidine
2,4-diamino-5-[3-(2-methoxy-5-phenylphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
2,4-diamino-5-[3-(2-phenyl-5-methoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
-
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)-3-methylbut-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)pent-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3,4,5-trimethoxyphenyl)prop-1-ynyl]-6-ethylpyrimidine
2,4-diamino-5-[3-(3-methoxy-4-(2,6-diisopropylphenyl)phenyl)-but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-4-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-diisopropylphenyl)phenyl)-but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-5-[3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-(2-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-(4-methoxyphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-(4-tertbutylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-(6-methylphenyl)phenyl)but-1-ynyl]-6-methylpyrimidine
2,4-diamino-5-[3-(3-methoxy-5-phenylphenyl)but-1-ynyl]-6-methylpyrimidine
-
-
2,4-diamino-6-(2-hydroxydibenz[b,f]azepin-5-yl)methylpteridine
crystallization data
2,4-diamino-6-[(2',5'-dichloroanilino)methyl]pyrido[2,3-d]pyrimidine
2,4-diamino-6-[(3',4',5'-trichloroanilino)methyl]pyrido[2,3-d]pyrimidine
2,4-diamino-6-[N-(2,3,5-trichlorobenzyl)-N-ethylamino]quinazoline
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-cyclopropyl methylamino]quinazoline
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-ethylamino]quinazoline
2,4-diamino-6-[N-(2,5-dimethoxybenzyl)-N-propylamino]quinazoline
2,4-diamino-6-[N-(alpha-naphthyl)-N-ethylamino]quinazoline
2,4-diamino-6-[N-(benzyl)-N-ethylamino]quinazoline
2,4-diamino-6-[N-(beta-naphthyl)-N-cyclopropyl methylamino]-quinazoline
2,4-diamino-6-[N-(beta-naphthyl)-N-ethylamino]quinazoline
2,4-diamino-6-[N-(beta-naphthyl)-N-propylamino]quinazoline
2,4-diaminopyrimidine
2,4-diaminoquinazoline
2,4-Dimamino-6-butylpyrido[2,3-d]pyrimidine
-
-
2,4-Pentanedione
-
-
2-(2-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)ethoxy)ethanol
2-(2-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)ethoxy)ethanol
-
2-(3-(2-(hydroxyimino)-2-(pyridine-4-yl)-6,7-dimethylquinoxalin-2-yl)-1-(pyridine-4-yl)ethanone) oxime
i.e. 373265, a dual-site inhibitor, that targets both the substrate and cofactor binding site, docking modelling, overview
2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-L-glutamic acid
potent enzyme inhibitor with anti-cryptosporidial activity in cell culture, chemical synthesis, overview. The inhibitor forms several hydrogen bonds and van der Waals interactions with the DHFR active site residues, binding close to the nicotinamide ring of NADPH. The carbonyl oxygens of the catalytic D32 hydrogen bond with N3 of the inhibitor forming a fork that holds the inhibitor in optimal position bound to the enzyme
2-amino-4-oxo-6-methyl-5-phenylsulfanylthieno[2,3-d]pyrimidine
2-amino-5-(4-bromobenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-(4-chlorobenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-(4-methoxybenzyl)-6-methyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]-pyrimidin-4(3H)-one
2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-5-[(4-chlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-5-[(4-fluorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-(4-bromophenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol
-
2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d ]pyrimidin-4(3H)-one
2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-methyl-5-(4-nitrobenzyl)-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-6-methyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one
2-amino-6-methyl-5-[4-(trifluoromethoxy)benzyl]-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
-
-
2-amino-8-(1,3-benzodioxol-5-yl)-9-phenyl-1,9-dihydro-6H-purin-6-one
synthesis, overview
2-amino-8-(2-hydroxyphenyl)-9-phenyl-9H-purin-6-ol
-
2-amino-8-(4-methylphenyl)-9-phenyl-9H-purin-6-ol
-
2-amino-9-phenyl-8-(3,4,5-trimethoxyphenyl)-9H-purin-6-ol
-
2-amino-9-phenyl-8-[4-(propan-2-yl)phenyl]-9H-purin-6-ol
-
2-hydroxy-5-nitrobenzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0151 mM
2-methoxybenzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0033 mM
2-[(2-ethoxyethyl)sulfanyl]-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrilemonohydrate
-
docking score is -7.34 kcal/mol, interacts with Arg70, and Gln35, water-mediated interactions with Asn4
-
2-[(3-[3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl]prop-2-yn-1-yl)oxy]benzoic acid
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]ethanol
2-[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(methyl)amino]-2-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethanol
2-[(E)-([2-amino-4-methoxy-6-(phenylamino)pyrimidin-5-yl]imino)methyl]phenol
synthesis, overview
2-[[(4-nitrophenyl)methyl]sulfanyl]-6-oxo-4-propyl-1,6-dihydropyrimidine-5-carbonitrile
-
docking score is -8.53 kcal/mol, interacts with Gln35, Asn64, and Ser59 via water, and with Val115, Phe34, Phe31
-
2-[[(4-[[(2-amino-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidin-6-yl)methyl]amino]phenyl)carbonyl]amino]hexanedioic acid
-
-
2-[[1-(3-chlorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl]-N-prop-2-en-1-ylhydrazinecarbothioamide
-
-
3,4-dichlorobenzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0037 mM
3,5-bis(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0056 mM
3-((3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenoxy)methyl)benzoic acid
3-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)propanoic acid
-
3-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)propanoic acid
-
3-(2,4-diamino-6-methylpyrimidin-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol
3-(2,4-diaminophenyl)-1-(3-(4-methylbenzyloxy)phenyl)prop-2-en-1-one
3-(2,4-diaminopyrimidin-5-yl)-1-(4-methoxyphenyl)-prop-2-en-1-one
3-(2-(3-[(2,4-diamino-6-ethylpyrimidin-5-yl)oxy]propoxy)phenyl)propanoic acid
i.e. P218, a registered candidate drug in human clinical trial
-
3-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)benzonitrile
-
3-(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0043 mM
3-([(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]amino)-4-(2,5-dimethoxyethoxy)phenol
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 7.6
3-benzyl-6-[(3,4-dimethoxybenzyl)(methyl)amino]-2-(methylsulfanyl)quinazolin-4(3H)-one
-
50% inhibition at 0.001 mM
3-benzyl-6-[(4-methoxybenzyl)(methyl)amino]-2-(methylsulfanyl)quinazolin-4(3H)-one
-
50% inhibition at 0.0005 mM
3-heptyl-4-hydroxy-1H-naphthalen-2-one
-
IC50: 0.48 mM, 0.03 mM 7,8-dihydrofolate
3-methoxybenzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0038 mM
3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin
-
i.e. TMECG, synthesis of a trimethoxy derivative of epicatechin-3-gallate, which shows high antiproliferative and proapoptotic activity against melanoma. It is a prodrug that is selectively activated by the specific melanocyte enzyme tyrosinase. Upon activation, the compound generates a stable quinone methide product that strongly inhibits dihydrofolate reductase in an irreversible manner. The treatment of melanoma cells affects cellular folate transport and the gene expression of DHFR
3-[(3-(3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl)prop-2-yn-1-yl)oxy]benzoic acid
ratio of IC50 values human/Trypanosoma enzyme is 77
3-[(3-[3-[(2,4-diaminopyrimidin-5-yl)methyl]-4-methoxyphenyl]prop-2-yn-1-yl)oxy]benzoic acid
ratio of IC50 values human/Trypanosoma enzyme is 77
3-[[(4-chlorophenyl)sulfonyl]methyl]-N'-hydroxybenzenecarboximidamide
-
-
4,5-dideoxy-5-(2,6-diamino-5-phenylpyrimidin-4-yl)-D-erythro-pentitol
-
selective inhibition, little effect on human or yeast enzyme
4,6-di(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.020 mM
4,6-di(morpholin-4-yl)-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.0258 mM
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines
-
bearing a terminal sulfonyl fluoride
4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)-N-(4-sulfamoylphenethyl)-benzamide
-
4-((2,4-diaminopteridin-6-yl)methylamino)-N-(4-sulfamoylphenethyl)benzamide
-
4-((2,4-diaminopteridin-6-yl)methylamino)benzenesulfonamide
-
4-((2,4-diaminopteridin-6-yl)methylamino)benzenesulfonic acid
-
4-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-(naphthalen-1-yl)ethyl)amino)butanoic acid
4-((5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)[1-(naphthalen-1-yl)ethyl]amino)butanoic acid
-
4-((5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl)ethynyl)benzoic acid
4-(2-(4-((2,4-diaminopteridin-6-yl)methylamino)benzamido)ethyl) benzenesulfonic acid
-
4-(2-methylpropyl)-2-[[(4-nitrophenyl)methyl]sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carbonitrile
-
docking score is -8.34 kcal/mol, interacts with Gln35, Asn64, and Val8 via water
-
4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenol
competitive inhibition
-
4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoic acid
4-(benzyloxy)benzaldehyde thiosemicarbazone
-
-
4-(N-[(2,4-Diamino-6-pteridyl)methyl]-N-methylamino)benzoate
-
-
4-(trifluoromethyl)benzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.013 mM
4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoic acid
4-([5-[(2,4-diaminopteridin-6-yl)methyl]-5H-dibenzo[b,f]azepin-2-yl]oxy)butane-1,1-diol
O-(3-carboxypropyl) inhibitor, crystallization data
4-benzyl-N-[3-benzyl-2-(methylsulfanyl)-4-oxo-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.008 mM
4-bromo-N-[2-(methylthio)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.002 mM
4-chloro-N-[4-(hydroxycarbamimidoyl)benzyl]benzamide
-
-
4-methylbenzyl N-[amino(imino)methyl]imidothiocarbamate
50% inhibition at 0.0126 mM
4-[(3,5-dichloropyridin-4-yl)oxy]-N'-hydroxybenzenecarboximidamide
-
-
4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]phenol
4-[3-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)benzamido]benzene-1-sulfonyl fluoride
contains a fluorosulfonylphenylaminocarbonyl substitution at R2 on 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine ring, and shows the unique behavior of tight-binding and average inhibition, uncompetitive versus NADPH, competitive versus 7,8-dihydrofolate
4-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]butanoic acid
50% inhibition of growth in culture at 0.00060 mM
4-[4,6-diamino-2-(4-chlorophenyl)-1,3,5-triazin-1(2H)-yl]benzene-1-sulfonamide
-
4-[4-[3-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenyl]butyl]benzenesulfonyl fluoride
uncompetitive versus NADPH, competitive versus 7,8-dihydrofolate
4-[6-[4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenyl]hexyl]benzenesulfonyl fluoride
uncompetitive versus NADPH, competitive versus 7,8-dihydrofolate
4-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy]benzaldehyde thiosemicarbazone
-
-
5,5'-dithiobis(2-nitrobenzoate)
5,6,7,8-tetrahydrofolate
-
non-competitive product inhibition
5-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-pyrimidine-2,4-diamine
5-((4-methoxyphenylamino)methyl)pyrimidine-2,4-diamine
5-((5H-dibenzo[b,f]azepin-5-yl)methyl)pyrimidine-2,4-diamine
5-((benzo[d]oxazol-2-ylthio)methyl)pyrimidine-2,4-diamine
5-((methyl(naphthalen-1-yl)amino)methyl)pyrimidine-2,4-diamine
5-((naphthalen-1-ylamino)methyl)pyrimidine-2,4-diamine
5-(3,4,5-trimethoxy-benzyl)-pyrimidine-2,4-diamine
-
IC50: 18 nM, 0.03 mM 7,8-dihydrofolate
5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(3-chlorophenyl)-6-(3-phenylpropyl)pyrimidine-2,4-diamine
-
5-(3-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(4-bromophenyl)-6-ethylpyrimidine-2,4-diamine
5-(4-chlorophenyl)-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamine
competitive inhibition
-
5-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidine-2,4-diamine
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(4-chlorophenyl)-6-isobutylpyrimidine-2,4-diamine
5-(4-chlorophenyl)-6-isopropylpyrimidine-2,4-diamine
5-(4-chlorophenyl)-6-phenylpyrimidine-2,4-diamine
5-(4-chlorophenyl)-6-propylpyrimidine-2,4-diamine
5-(5-[[(2,4-diamino-6-quinazolinyl)methyl](propyl)amino]-2-methoxyphenoxy) pentanoate
5-(methoxymethyl)-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-ethyl-6-(phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine
5-ethyl-6-[(4-methoxyphenyl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(4-nitrophenyl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(naphthalen-1-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(naphthalen-2-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[(quinolin-8-yl)sulfanyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
5-ethyl-6-[[(2-methoxy-5-methylphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
5-fluorodeoxyuridine monophosphate
-
5-fluorouracil
-
5-methoxy-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
5-methyl-6-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(5,6,7,8-tetrahydronaphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-1-ylsulfanyl)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-2-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(naphthalen-2-ylsulfanyl)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
5-methyl-6-[(pyren-1-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-3-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-5-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[(quinolin-6-ylamino)methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
5-methyl-6-[[(3,4,5-trimethoxyphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
5-methyl-6-[[(3-methylphenyl)sulfanyl]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
5-methyltetrahydrofolate
-
-
5-nitro-6-methylamino-isocytosine
inhibitor of dihydropteroate synthase, also acts on dihydrofolate reductase
5-phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine
-
selective inhibition of Mycobacterium tuberculosis enzyme, little effect on human or yeast enzyme
5-[(E)-benzylideneamino]-6-methoxy-N4-phenylpyrimidine-2,4-diamine
-
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine
5-[(R/S)-2-(2'-methoxyphenyl)-3-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine
5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine
5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine
5-[(R/S)-2-cyclopropyl-2-(2'-methoxyphenyl)ethyl]furo-[2,3-d]pyrimidine-2,4-diamine
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylbut-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
5-[(Z/E)-2-(2'-methoxyphenyl)-3-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
5-[(Z/E)-2-(2'-methoxyphenyl)-4-methylpent-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine
5-[(Z/E)-2-(2'-methoxyphenyl)hex-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
5-[(Z/E)-2-(2'-methoxyphenyl)pent-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine
5-[(Z/E)-2-cyclopropyl-2-(2'-methoxyphenyl)vinyl]furo-[2,3-d]pyrimidine-2,4-diamine
5-[3-(2,5-dimethoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-propylpyrimidine-2,4-diamine
-
5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
5-[3-(2-methoxy-2',6'-dimethylbiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(2-methoxy-2'-methylbiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(3-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(5-methoxy-2'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
-
5-[3-(5-methoxy-3',5'-dimethyl[1,1'-biphenyl]-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(5-methoxy[1,1'-biphenyl]-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-(biphenyl-3-yl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
-
5-[3-methoxy-3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]pentanoic acid
50% inhibition of growth in culture at 0.00167 mM
5-[3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]but-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
5-[3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine
5-[3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
5-[3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine
6,6-dimethyl-1-(4-methylphenyl)-1,6-dihydro-1,3,5-triazine-2,4-diamine
-
6,6-dimethyl-1-[3-(4-phenylbutyl)phenyl]-1,6-dihydro-1,3,5-triazine-2,4-diamine
uncompetitive versus NADPH, competitive versus 7,8-dihydrofolate
6,7-bis(4-aminophenyl)pteridine-2,4-diamine
NSC61642
6,7-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
-
IC50: 790 nM, 0.03 mM 7,8-dihydrofolate
6-((10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)methyl)-1,3,5-triazine-2,4-diamine
6-((10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
6-((2-chloro-10H-phenothiazin-10-yl)methyl)-1,3,5-triazine-2,4-diamine
6-((5-methoxy-2-methylphenylamino)methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-(([4-chlorotricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]amino)methyl)pteridine-2,4-diamine
6-(2-(5H-dibenzo[b,f]azepin-5-yl)ethoxy)pyrimidine-2,4-diamine
6-(2-[4-(benzyloxy)phenyl]ethyl)quinazoline-2,4-diamine
6-(3,4,5-trimethoxybenzyloxy)pyrimidine-2,4-diamine
6-(4-trifluoromethyl-phenoxy)-quinazoline-2,4-diamine
-
IC50: 660 nM, 0.03 mM 7,8-dihydrofolate
6-([(1E)-(4-methoxyphenyl)methylene]amino)-2-(methylthio)-3-phenylquinazolin-4(3H)-one
-
50% inhibition at 0.002 mM
6-([(2,5-dipropoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 65
6-([(2-bromo-3,4,5-trimethoxyphenyl)amino]methyl)quinazoline-2,4-diamine
50% inhibition of growth in culture at 0.0011 mM
6-([(2-butoxy-5-ethoxyoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 2.8
6-([(2-butoxy-5-propoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 19
6-([(2-ethoxy-5-butoxyphenyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
ratio of IC50 of human to Mycobacterium tuberculosis enzyme 4.1
6-([(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
6-([(4-aminophenyl)amino]methyl)pteridine-2,4-diamine
6-([(4-ethoxyphenyl)amino]methyl)pteridine-2,4-diamine
6-([5-quinolylamino]-methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine
enzyme-bound crystal structure analysis for inhibitor screening and docking studies, PDB ID 1KMS
6-([butyl(phenyl)amino]methyl)pteridine-2,4-diamine
6-([ethyl(phenyl)amino]methyl)pteridine-2,4-diamine
6-([methyl(3-nitrophenyl)amino]methyl)pteridine-2,4-diamine
6-([methyl(phenyl)amino]methyl)pteridine-2,4-diamine
6-([phenyl(prop-2-en-1-yl)amino]methyl)pteridine-2,4-diamine
6-([phenyl(propan-2-yl)amino]methyl)pteridine-2,4-diamine
6-([phenyl(propyl)amino]methyl)pteridine-2,4-diamine
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylamino]methyl)pteridine-2,4-diamine
6-([tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-ylamino]methyl)pteridine-2,4-diamine
6-([[2-(difluoromethoxy)-5-methylphenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-([[2-(difluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-([[2-bromo-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-([[2-fluoro-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-([[2-methoxy-5-(trifluoromethyl)phenyl](methyl)amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-([[2-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-([[3-methoxy-5-(trifluoromethyl)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-([[4-(difluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-([[4-(fluoromethoxy)phenyl]amino]methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-amino-3-pentadecylphenyl beta-D-glucoside
i.e. 1357, a dual-site inhibitor, that targets both the substrate and cofactor binding site
6-ethyl-5-(4-methoxyphenyl)pyrimidine-2,4-diamine
6-ethyl-5-phenylpyrimidine-2,4-diamine
analogue of pyrimethamine lacking the 4-Cl group, effectively inhibits both wild-type and pyrimethamine-resistant mutant S58R/S117N
6-ethyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
6-ethyl-5-[3-(4-methoxybiphenyl-3-yl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
-
6-ethyl-5-[3-[2-methoxy-5-(pyridin-4-yl)phenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
6-ethyl-5-[3-[3-(isoquinolin-5-yl)-5-methoxyphenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
6-ethyl-5-[3-[3-(isoquinolin-5-yl)-5-methoxyphenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
6-ethyl-5-[3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
6-ethyl-5-[3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine
6-ethyl-5-[3-[3-methoxy-5-(pyrimidin-5-yl)phenyl]prop-1-yn-1-yl]pyrimidine-2,4-diamine
6-methoxy-5-[(E)-[(4-methylphenyl)methylidene]amino]-N~4~-phenylpyrimidine-2,4-diamine
-
6-methoxy-N~4~-phenyl-5-[(E)-[(pyridin-4-yl)methylidene]amino]pyrimidine-2,4-diamine
-
6-methoxy-N~4~-phenyl-5-[(E)-[[4-(trifluoromethyl)phenyl]methylidene]amino]pyrimidine-2,4-diamine
-
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine
6-methyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-yn-1-yl]pyrimidine-2,4-diamine
6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine
6-p-tolyloxy-quinazoline-2,4-diamine
-
IC50: 190 nM, 0.03 mM 7,8-dihydrofolate
6-p-tolylsulfanyl-quinazoline-2,4-diamine
-
IC50: 310 nM, 0.03 mM 7,8-dihydrofolate
6-[(2,4-dichlorophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(2,5-dimethoxyphenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(2,6-dimethylphenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(3,4-dichlorophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(3,4-dimethoxyanilino)methyl]-2,4-quinazolinediamine
6-[(4-bromophenyl)sulfanyl]-5-ethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
-
6-[(4-methoxybenzyl)(methyl)amino]-2-(methylsulfanyl)-3-phenylquinazolin-4(3H)-one
-
50% inhibition at 0.001 mM
6-[(9H-fluoren-2-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(9H-fluoren-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(anthracen-9-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(fluoranthen-3-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(isoquinolin-5-ylamino)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[(phenylamino)methyl]pteridine-2,4-diamine
6-[(tricyclo[4.3.0.07,9]nona-1,3,5-trien-3-ylamino)methyl]pteridine-2,4-diamine
6-[2-(2,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[2-(3,5-dimethoxyphenyl)ethyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[2-(4-butoxyphenyl)ethyl]quinazoline-2,4-diamine
6-[2-(4-ethoxyphenyl)ethyl]quinazoline-2,4-diamine
6-[2-(4-hexoxyphenyl)ethyl]quinazoline-2,4-diamine
6-[2-(4-octyloxyphenyl)ethyl]quinazoline-2,4-diamine
6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]hexanoic acid
50% inhibition of growth in culture at 0.00051 mM
6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenyl]hex-5-ynoic acid
50% inhibition of growth in culture at 0.00190 mM
6-[[(2,5-dibromophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dibutoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(2,5-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-diethoxyphenyl)(methyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(2,5-diethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-difluorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-ethylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2,5-dipropoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(2-chloro-4,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2-chloro-4-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2-chloro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2-fluoro-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,4,5-trimethoxyphenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,4-dichlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,4-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,4-dimethoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3,5-dimethoxyphenyl)(methyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(3,5-dimethoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-bromo-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-chloro-4-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(3-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-ethoxy-5-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(3-fluoro-4-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-methoxy-5-propoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(3-methoxybiphenyl-4-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(3-methoxyphenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-bromo-2,6-dimethylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-bromo-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-bromo-3-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-butoxy-3-methoxyphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chloro-2-methoxy-5-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-chloronaphthalen-1-yl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-(methoxymethyl)pyrido[2,3-d]pyrimidine-2,4-diamine
-
-
6-[[(4-chlorophenyl)amino]methyl]-5-methoxypyrido[2,3-d]pyrimidine-2,4-diamine
-
6-[[(4-chlorophenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-chlorophenyl)amino]methyl]pyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(4-chlorophenyl)sulfanyl]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(5-chloro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(5-fluoro-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
6-[[(5-methoxy-2-methylphenyl)amino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
-
-
7,8-dihydrofolate
-
substrate inhibition at concentration above 0.008 mM for native enzyme and at concentration above 0.001 mM for the recombinant enzyme
7-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
-
IC50: 0.011 nM, 0.03 mM 7,8-dihydrofolate
7-[(4-aminophenyl)methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
NSC309401, AMPQD, a substrate analogue with the quinazoline-1, 3-diamine group, tight-binding inhibitor, complete inhibition at 1 mM, competitive inhibition of dihydrofolate binding. Potently inhibits the enzyme by competitive displacement of the substrate dihydrofolic acid, uncompetitive inhibition versus NADPH, the inhibitor has a markedly increased affinity for the NADPH-bound form of the enzyme. The mode of binding of the inhibitor to the enzyme-NADPH binary complex conforms to the slow-onset, tight-binding model
7-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenyl]hept-6-ynoic acid
50% inhibition of growth in culture at 0.000027 mM
7-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]hept-6-ynoic acid
7H-pyrrolo(3,2-f)quinazoline-1,3-diamine
NSC339578
7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
PQD, the lack of (4-aminophenyl)-methyl group at position 7 abolishes the slow-onset of inhibition
aminopterin
AR-101
i.e. 5-[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-ylmethyl]pyrimidine-2,4-diamine, binding structure from crystal structure, the cyclopropyl-dimethoxychromene moiety interacts with the conserved residues Leu28, Val31, Ile50 and Leu54 forming a hydrophobic pocket in the enzyme
Ar-102
i.e. 5-[(2S)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-ylmethyl]pyrimidine-2,4-diamine, binding structure from crystal structure, the cyclopropyl-dimethoxychromene moiety interacts with the conserved residues Leu28, Val31, Ile50 and Leu54 forming a hydrophobic pocket in the enzyme
atherospermidine
BAL0030543
BAL0030544
BAL0030545
benzaldehyde semicarbazone
-
-
Bromoacetate
-
-
chaotrophes
-
chlorocycloguanil
-
-
Chloroquine
citrate
-
in acid pH range: inhibitor of reduction of 7,8-dihydrofolate but not folate
ClO4-
cycloguanil
Dansyl chloride
-
-
deoxytubulosine
Diaminobutane
-
12 mM
Diaminopentane
-
12 mM
Dichloromethotrexate
-
-
diethyldicarbonate
dihydrofolic acid
-
DMSO
irreversibly impairs the enzymatic activity at 30% v/v
epicatechin gallate
-
epicatechin-3-O-gallate
-
-
epigallocatechin gallate
epigallocatechin-3-gallate
epigallocatechin-3-O-gallate
-
-
ethyl 4-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) butanoate
ethyl 4-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]butanoate
50% inhibition of growth in culture at 0.00088 mM
ethyl 5-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]pentanoate
50% inhibition of growth in culture at 0.00035 mM
ethyl 6-[3-[(2,4-diamino-5-methylpyrido[2,3-d]pyrimidin-6-yl)methyl]-4-methoxyphenoxy]hexanoate
50% inhibition of growth in culture at 0.00185 mM
ethylenediamine
-
12 mM
folate
folic acid
-
use in yeast protein fragment complementation assay system to prevent endogenous dihydrofolate reductase activity
grape seed extract
-
grape seed extract inhibits the dihydrofolate reductase activity and growth of Staphylococcus aureus. The grape seed extract-induced growth inhibition is reversed by adding, tetrahydrofolate, 5,10-methylenetetrahydrofolate or methionine to the medium
-
Guanidine-HCl
hydrochlorothiazide
sulfonamide diuretic, able to bind to DHFR
iclaprim
binding structure from crystal structure
indapamide
sulfonamide diuretic, able to bind to DHFR
iodoacetamide
isomoschatoline
isoniazid
acyclic 4R isonicotinoyl-NADP adduct binds to enzyme
KCl
-
recombinant enzyme, concentration above 0.1 M
L-erythro-biopterin
-
-
L-tryptophyl-L-tyrosyl-L-tyrosine
-
development of a tri-peptide inhibitor using a structure-based drug design approach, docking studies and molecular dynamics, overview
liriodenine
melosmine
Mercuric chloride
-
-
methasquin
-
-
methopterin
methotrexate
methyl 4-(2,6-diamino-5-phenylpyrimidin-4-yl)butanoate
methyl 4-([(2,4-diaminopteridin-6-yl)methyl](methyl)amino)benzoate
methyl 4-[(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) methyl]benzene carboxylate
methyl 4-[2,6-diamino-5-(3-chlorophenyl)pyrimidin-4-yl]butanoate
methyl 5-(5-[(2,4-diamino-6-quinazolinyl)methyl]amino-2-methoxyphenoxy) pentanoate
methyl 5-[(1E)-N-carbamoylethanehydrazonoyl]-2,3'-bithiophene-5'-carboxylate
-
-
methylbenzoprim
NSC382035
methylene blue
-
-
methylmercuric hydroxide
-
-
N-(4-chloro-2-cyanophenyl)imidodicarbonimidic diamide
-
IC50: 320 nM, 0.03 mM 7,8-dihydrofolate
N-(4-nitrophenyl)-4,6-di(piperidin-1-yl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.130 mM
N-(4-nitrophenyl)-4,6-di(pyrrolidin-1-yl)-1,3,5-triazin-2-amine
-
minimal inhibitory concentration: 0.140 mM
N-(4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl)-L-glutamic acid
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d ]pyrimidin-5-yl)thio]benzoyl)-L-glutamic acid
N-(4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl)-L-glutamic acid
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
N-(4-[[(4-amino-2-[[(2,4,6-trifluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]benzoyl)-L-glutamic acid
halogenated derivative of methotrexate, binding affinity value -34.73 kJ/mol
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)-beta-alanine
-
N-(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)-N-[1-(2-ethoxynaphthalen-1-yl)ethyl]-b-alanine
N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid
-
-
N-bromosuccinimide
-
-
N-ethylmaleimide
N-[(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]phenyl)carbonyl]glutamic acid
50% inhibition of growth in culture at 0.000024 mM
N-[2-(methylsulfanyl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]biphenyl-4-sulfonamide
-
50% inhibition at 0.005 mM
N-[2-(methylthio)-4-oxo-3-phenyl-3,4-dihydroquinazolin-6-yl]benzenesulfonamide
-
50% inhibition at 0.002 mM
N-[3-benzyl-2-(methylsulfanyl)-4-oxo-3,4-dihydroquinazolin-6-yl]-4-methylbenzenesulfonamide
-
50% inhibition at 0.007 mM
N-[3-benzyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-6-yl]-4-bromobenzenesulfonamide
-
50% inhibition at 0.005 mM
N-[3-[[2-[(2,4-diaminopyrimidin-5-yl)amino]ethyl](methyl)amino]prop-2-ynoyl]glutamic acid
-
N-[4-[(2,4-diamino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)sulfanyl]benzoyl]glutamic acid
-
N-[4-[(2,4-diamino-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)sulfanyl]benzoyl]glutamic acid
-
N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)-thio]-benzoyl]-L-glutamic acid
N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-2-(trifluoroacetyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.98 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-3-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.56 kJ/mol
-
N-[4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]-5-fluoro-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N-[4-[[(2E)-2-[(2,4-diaminopyrimidin-5-yl)imino]ethyl](methyl)amino]benzoyl]glutamic acid
-
N-[4-[[(4-amino-2-[[(2,4-difluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -36.40 kJ/mol
-
N-[4-[[(4-amino-2-[[(4-fluorophenyl)carbamoyl]amino]pteridin-6-yl)methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, binding affinity value -34.73 kJ/mol
-
N-[4-[[2-[(2,4-diaminopyrimidin-5-yl)amino]ethyl](methyl)amino]benzoyl]glutamic acid
-
N-[4-[[[4-amino-2-([[4-(trifluoromethyl)phenyl]carbamoyl]amino)pteridin-6-yl]methyl](methyl)amino]-2-(trifluoromethyl)benzoyl]-L-glutamic acid
halogenated derivative of methotrexate, shows better binding affinity and a good number of hydrogen and other non-bonding interactions. Binding affinity value -35.14 kJ/mol
-
N-[6-amino-5-(4-methoxyphenyl)-4,4-dimethyl-4,5-dihydrotriazin-2-yl]acetamide
competitive inhibition
-
N10-formylaminopterin
N10-propargyl-5,8-dideazafolate
PDDF, a TS folate inhibitor, binds at the TS active site
N2,N2,N4,N4-tetraethyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.027 mM
N2,N4-bis(3-fluorophenyl)-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.022968 mM
N2,N4-bis[2-(morpholin-4-yl)ethyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0042 mM
N2,N4-bis[3-(1H-imidazol-1-yl)propyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0021 mM
N2,N4-bis[3-(morpholin-4-yl)propyl]-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0039 mM
N2,N4-di-tert-butyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.139 mM
N2,N4-dibenzyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.023393 mM
N2,N4-dibutyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0055 mM
N2,N4-dicycloheptyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0041 mM
N2,N4-dicyclohexyl-N6-(4-nitrophenyl)-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.0024 mM
N2-(4-nitrophenyl)-N4,N6-dioctyl-1,3,5-triazine-2,4,6-triamine
-
minimal inhibitory concentration: 0.021 mM
N6-(2,5-dimethoxybenzyl)-N6-methylpyrido[2,3-d]pyrimidine-2,4,6-triamine
N6-(2,5-dimethoxybenzyl)-N6-methylquinazoline-2,4,6-triamine
N6-(2,5-dimethoxybenzyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
N6-(2,5-dimethoxybenzyl)quinazoline-2,4,6-triamine
N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
N6-methyl-N6-(4-isopropylphenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine
N6-methyl-N6-1-naphthylpyrido[2,3-d]pyrimidine-2,4,6-triamine
N6-methyl-N6-phenylpyrido[2,3-d]pyrimidine-2,4,6-triamine
N7-(1-(naphthalen-1-yl)ethyl)-N7-propylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(2-aminoethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(2-aminoethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(2-ethoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(2-ethoxyethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(2-propoxyethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(2-propoxyethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(3-ethoxypropyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(3-ethoxypropyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(4-aminobutyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(4-aminobutyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(5-aminopentyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(5-aminopentyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(cyclopropylmethyl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(cyclopropylmethyl)-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(cyclopropylmethyl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-(prop-2-en-1-yl)-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-(prop-2-en-1-yl)-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-benzyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-benzyl-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-benzyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-butyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-butyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-cyclopropyl-N7-(1-(naphthalen-2-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-cyclopropyl-N7-[1-(naphthalen-2-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-ethyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-ethyl-N7-(4-methylbenzyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-ethyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-methyl-N7-(1-phenylethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-methyl-N7-(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-yl]ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-methyl-N7-[1-(4-methylnaphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-methyl-N7-[1-(quinolin-4-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-methyl-N7-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-7-ylmethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-pentyl-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-pentyl-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-ethylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(1-benzothiophen-3-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(2-ethoxynaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(2-ethylnaphthalen-1-yl)ethyl]-N7-methylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(4-chloronaphthalen-1-yl)ethyl]-N7-(cyclopropylmethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[1-(naphthalen-1-yl)ethyl]-N7-propylpyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[2-(4-fluorophenyl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[2-(4-fluorophenyl)ethyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[2-(cyclohex-2-en-1-yl)ethyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[2-(cyclohex-2-en-1-yl)ethyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[3-(2-methyl-4H-imidazol-4-yl)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[3-(2-methyl-4H-imidazol-4-yl)propyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
N7-[3-(2-methylpropoxy)propyl]-N7-(1-(naphthalen-1-yl)ethyl)pyrimido[4,5-d]pyrimidine-2,4,7-triamine
N7-[3-(2-methylpropoxy)propyl]-N7-[1-(naphthalen-1-yl)ethyl]pyrimido[4,5-d]pyrimidine-2,4,7-triamine
-
NaCl
-
up to 20% increase in activity up to 0.2 M, activity declines above and falls to zero at 0.8 M
NADP+
NCI0086195
-
docking analysis, overview
NCI0109835
-
docking analysis, overview
NCI0156252
-
docking analysis, overview
NCI0164641
-
docking analysis, overview
NCI0211175
-
docking analysis, overview
NCI0289533
-
docking analysis, overview
NCI0289541
-
docking analysis, overview
NCI0309401
-
docking analysis, overview
NCI0369769
-
docking analysis, overview
NCI0696662
-
docking analysis, overview
NH4+
-
activation of mutant type enzyme at 0.2 mM, decrease of wild-type enzyme activity above 0.1 mM
nolatrexed
OAAG324
-
i.e. 6-([(2,5-dichlorophenyl)amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine, 50% inhibition at 0.000262 mM, recombinant rat-derived enzyme, 50% inhibition at 0.0075 mM, recombinant human-derived enzyme
OAAG373
-
i.e. 6-([(3,4,5-trichlorophenyl)amino]methyl)pyrido[2,3-d]pyrimidine-2,4-diamine, 50% inhibition at 0.000139 mM, recombinant rat-derived enzyme, 50% inhibition at 0.00094 mM, recombinant human-derived enzyme
organic mercurials
-
p-chloromercuribenzoate
p-hydroxymercuribenzoate
p-mercuribenzoate
-
mutant enzyme: no effect, wild type: inhibition
pegularinine
-
plant alkaloid
pemetrexed
permetrexed
peroxynitrite
-
0.1 mM, 50% inhibition of cysteine-free mutant C85S/C152E, no inhibition of wild-type
Phenylglyoxal
-
total inactivation
phenylmercuric acetate
-
mutant enzyme: no effect, wild type enzyme: inhibition
piritrexim
plevitrexed
pralatrexate
proguanil
-
-
PT682
-
O-(3-carboxypropyl) inhibitor, crystallization data
Pteroate
-
-
PY957
pyrimethamine
quinone methide
-
essentially irreversible inhibition
RAB1
i.e. (S,E)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-propylphthalazin-2(1H)-yl)prop-2-en-1-one or BAL17662, a dihydrophthalazine-based trimethoprim derivative, synthesis, overview. Binding of RAB1 causes a conformational change of the side chain of Arg58 and Met37 to accommodate the dihydrophthalazine moiety. The dihydrophthalazine group provides a large hydrophobic anchor that embeds within the DHFR active site and accounts for its selective inhibitory activity against Bacillus anthracis, binding structure, overview
raltitrexed
Rose bengal
-
-
SANC00368
-
SANC00470
-
Sodium dodecyl sulfate
-
recombinant enzyme, 0.1 M
Sodium tetrathionate
-
thiol-blocking reagent
spermidine
-
12 mM
spermine
-
12 mM
sulfanilamide
-
use in yeast protein fragment complementation assay system to prevent endogenous dihydrofolate reductase activity
tetrahydrofolate
-
product inhibition
triaminopyrimidine
-
Triampterene
-
-
Triazinate
-
-
triclosan
trimepthoprim
-
-
trimethoprim
trimethoprim-sulfamethoxazole
resistance of enterobacteria generally occurs through the acquisition of a TMP-insensitive DHFR
trimetrexate
tylophorinidine
-
plant alkaloid
-
vitexin
WR99210
ZINC00057846
-
ZINC00359797
-
ZINC0058117
-
ZINC00612219
-
ZINC00630525
-
ZINC00677623
-
ZINC00809143
-
ZINC01003765
-
ZINC02177983
-
ZINC02184332
-
ZINC02690799
-
ZINC04313814
-
ZINC04523829
-
ZINC04671320
-
ZINC06556964
-
ZINC08992677
-
[(5,7-diaminopyrimido[4,5-d]pyrimidin-2-yl)(1-[tricyclo[4.4.0.02,5]deca-1(10),2(5),6,8-tetraen-8-yl]ethyl)amino]acetic acid
[amino-(4-[[(amino-thioureido-methyl)-amino]-methyl]-2,5-dimethyl-benzylamino)-methyl]-thiourea
-
IC50: 109 nM, 0.03 mM 7,8-dihydrofolate
additional information
-